Stefan Zschiedrich
Overview
Explore the profile of Stefan Zschiedrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhn C, Janigen B, Matuschik L, Rieger M, Sidler D, Zschiedrich S
BMC Nephrol
. 2025 Feb;
26(1):59.
PMID: 39915729
Background: Despite advances in kidney transplant surgery and immunosuppression, lymphoceles remain a frequent complication in the early postoperative period following kidney transplantation, often requiring reintervention. While long-term outcomes such as...
2.
Kirste S, Ruhle A, Zschiedrich S, Schultze-Seemann W, Jilg C, Neumann-Haefelin E, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291853
Von Hippel-Lindau disease (VHL) is a hereditary disorder associated with malignant tumors including clear cell renal cell carcinoma (ccRCC). Partial nephrectomy is complicated by multilocular tumor occurrence and a high...
3.
Henningsen M, Jaenigen B, Zschiedrich S, Pisarski P, Walz G, Schneider J
Transplant Proc
. 2021 May;
53(5):1589-1598.
PMID: 34020796
Background: Leukopenia is a common complication after kidney transplantation. The etiology is multifactorial, with medication adverse effects and cytomegalovirus infection as main causes. Optimal strategies to prevent or treat posttransplant...
4.
Emmerich F, Zschiedrich S, Reichenbach-Braun C, Susal C, Minguet S, Pauly M, et al.
Molecules
. 2021 May;
26(9).
PMID: 33946587
Acute and chronic transplant rejections due to alloreactivity are essential contributors to graft loss. However, the strength of alloreactivity is biased by non-immunological factors such as ischemia reperfusion injury (IRI)....
5.
Langhorst C, Ganner A, Schneider J, Prager E, Walz G, Pisarski P, et al.
Transplant Proc
. 2020 Oct;
53(3):848-855.
PMID: 33041078
Background: ABO-incompatible kidney transplantation (ABOi-KT) is an established way to enlarge the donor pool around the world. Comparability of long-term success and complications to ABO-compatible kidney transplantation (ABOc-KT) are still...
6.
Darr R, Kater J, Sekula P, Bausch B, Krauss T, Bode C, et al.
Endocr Connect
. 2020 Sep;
9(8):834-844.
PMID: 32869749
The optimal treatment strategy for patients with small non-functioning VHL-related incidentalomas is unclear. We searched the Freiburg VHL registry for patients with radiologic evidence of pheochromocytoma/paraganglioma (PHEO/PGL). In total, 176...
7.
Vergauwen E, Steiert C, Kruger M, Jilg C, Zschiedrich S, Klingler J, et al.
Clin Neurol Neurosurg
. 2020 Aug;
197:106111.
PMID: 32758916
Objective: Patients affected with von Hippel-Lindau disease often develop multiple hemangioblastomas in the cerebellum and spinal cord. Timing of surgical intervention is difficult and depends largely on the anticipated surgical...
8.
Volker L, Kaufeld J, Miesbach W, Brahler S, Reinhardt M, Kuhne L, et al.
Blood Adv
. 2020 Jul;
4(13):3093-3101.
PMID: 32634237
Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX),...
9.
Volker L, Kaufeld J, Miesbach W, Brahler S, Reinhardt M, Kuhne L, et al.
Blood Adv
. 2020 Jul;
4(13):3085-3092.
PMID: 32634236
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in...
10.
Janigen B, Gehrmann S, Glatz T, Seidl M, Thomusch O, Prager E, et al.
Transplant Proc
. 2020 Mar;
52(3):780-784.
PMID: 32111386
Background: The recommended standard immunosuppressive therapy for renal transplant recipients comprises an initial induction therapy mainly with an interleukin-2-receptor antibody (IL2-RA) and a triple maintenance therapy. With tacrolimus and mycophenolate...